Telomir Pharmaceuticals, Inc.
TELO
$1.26
-$0.03-2.33%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 838.50K | 387.00K | 5.03M | 1.85M | 2.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.13M | 1.15M | 5.07M | 2.19M | 2.91M |
| Operating Income | -2.13M | -1.15M | -5.07M | -2.19M | -2.91M |
| Income Before Tax | -2.06M | -1.10M | -5.07M | -2.18M | -2.90M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.06M | -1.10M | -5.07M | -2.18M | -2.90M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.06M | -1.10M | -5.07M | -2.18M | -2.90M |
| EBIT | -2.13M | -1.15M | -5.07M | -2.19M | -2.91M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.06 | -0.03 | -0.17 | -0.07 | -0.10 |
| Normalized Basic EPS | -0.04 | -0.02 | -0.11 | -0.05 | -0.06 |
| EPS Diluted | -0.06 | -0.03 | -0.17 | -0.07 | -0.10 |
| Normalized Diluted EPS | -0.04 | -0.02 | -0.11 | -0.05 | -0.06 |
| Average Basic Shares Outstanding | 33.49M | 32.40M | 30.01M | 29.76M | 29.66M |
| Average Diluted Shares Outstanding | 33.49M | 32.40M | 30.01M | 29.76M | 29.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |